MedTrace Logo

Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica.

NCT06011512 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 198

Last updated 2026-04-30

No results posted yet for this study

Summary

The goal of this observational study is to expand the knowledge about development and aggreviation of diabetes mellitus in patients with giant cell arthritis and polymyalgia rheumatica.

The main questions it aims to answer are:

* To identify the risk of comorbidities, especially diabetes, in patients with giant cell arthritis and polymyalgia rheumatica, treated with glucocorticoids in combination with or without interleukin-6 inhibitor.
* To identify clinical outcomes and biomarkers as potential predictors for development or aggregation of already existing diabetes mellitus in patients with giant cell arthritis or polymyalgia rheumatica using machine learning prediction.

Participants will be followed at their respective rheumatology clinic, and will be asked to deliver blood samples at predefined visits.

Conditions

  • Giant Cell Arteritis
  • Polymyalgia Rheumatica
  • Large Vessel Vasculitis

Sponsors & Collaborators

  • Salome Kristensen

    lead OTHER

Principal Investigators

  • Salome Kristensen, MD, PhD · Aalborg University Hospital

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-09-01
Completion
2025-09-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06011512 on ClinicalTrials.gov